Literature DB >> 7677133

HIV infection among female partners of seropositive men in Brazil. Rio de Janeiro Heterosexual Study Group.

M D Guimarães1, A Muñoz, C Boschi-Pinto, E A Castilho.   

Abstract

A heterosexual partner study was carried out in Rio de Janeiro, Brazil, from August 1990 to December 1991. The main objectives were to determine the rate of male-to-female transmission of human immunodeficiency virus (HIV) and to determine risk factors. Male index cases were recruited according to the following criteria: 1) confirmed HIV positivity, 2) 18 years old or older; 3) heterosexual contact within the past year. Only female partners who reported not to have other risk factors but to have had sexual contact with the index case were invited to participate. Couples were interviewed for risk factors and had blood collected for laboratory studies. The overall prevalence of HIV infection was 45 percent among 204 female partners in the study. Using logistic regression, the authors found the following factors to be independently (p < 0.05) associated with HIV infection: 1) anal sex (odds ratio (OR) = 3.74, 95% confidence interval (CI) 1.87-7.45); 2) condom use during vaginal sex sometimes (OR = 1.45, 95% CI 1.07-1.96), rarely (OR = 2.10, 95% CI 1.15-3.83), or never (OR = 3.04, 95% CI 1.23-7.50) as compared with always; 3) frequency of sexual contacts in the year prior to interview (100+) (OR = 2.00, 95% CI 1.03-3.91); and 4) oral contraceptive use (OR = 2.04, 95% CI 0.97-4.29). In addition to a borderline significance of oral contraceptive use, there was a strong suggestion of an interaction with history of sexually transmitted diseases.

Entities:  

Mesh:

Year:  1995        PMID: 7677133     DOI: 10.1093/oxfordjournals.aje.a117672

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  7 in total

1.  Sexual behaviors and partner-specific correlates of heterosexual anal intercourse among truck drivers and their wives in South India.

Authors:  Tarun Bhatnagar; P Sakthivel Saravanamurthy; Roger Detels
Journal:  Arch Sex Behav       Date:  2014-09-25

2.  Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection.

Authors:  Grant R Yeaman; Alexandra L Howell; Sally Weldon; Douglas J Demian; Jane E Collins; Denise M O'Connell; Susana N Asin; Charles R Wira; Michael W Fanger
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

Review 3.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

Review 4.  HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention.

Authors:  Rebecca F Baggaley; Richard G White; Marie-Claude Boily
Journal:  Int J Epidemiol       Date:  2010-04-20       Impact factor: 7.196

5.  Anal intercourse among young heterosexuals in three sexually transmitted disease clinics in the United States.

Authors:  Pamina M Gorbach; Lisa E Manhart; Kristen L Hess; Bradley P Stoner; David H Martin; King K Holmes
Journal:  Sex Transm Dis       Date:  2009-04       Impact factor: 2.830

6.  Women's experiences with anal sex: motivations and implications for STD prevention.

Authors:  Emily Maynard; Alex Carballo-Diéguez; Ana Ventuneac; Theresa Exner; Kenneth Mayer
Journal:  Perspect Sex Reprod Health       Date:  2009-09

7.  First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.

Authors:  Peter A Anton; Terry Saunders; Julie Elliott; Elena Khanukhova; Robert Dennis; Amy Adler; Galen Cortina; Karen Tanner; John Boscardin; William G Cumberland; Ying Zhou; Ana Ventuneac; Alex Carballo-Diéguez; Lorna Rabe; Timothy McCormick; Henry Gabelnick; Christine Mauck; Ian McGowan
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.